Table 3.

RR of H. pylori and CagA status for future intestinal-type as well as diffuse-type noncardial gastric cancer

RR (95%CI)P
A. Noncardial gastric cancer, intestinal type
CAG2.2 (1.4-3.6)<0.001
H. pylori IgG(−)1.0 (reference)
H. pylori IgG(+), CagA < 152.5 (1.1-5.5)0.0240
H. pylori IgG(+), CagA ≥ 15, <239.9 (3.5-27.4)<0.001
H. pylori IgG(+), CagA ≥ 231.4 (0.8-2.7)0.26
Current smoker1.7 (0.9-3.2)0.073
Stomach dose (Gy), nonsmokers1.7 (0.5-2.8)0.26
Stomach dose (Gy), smokers0.8 (0.4-1.2)0.30
B. Noncardial gastric cancer, diffuse type
CAG2.4 (1.5-3.8)<0.001
H. pylori IgG(−)1.0 (reference)
H. pylori IgG(+), CagA < 152.2 (0.8-5.7)0.10
H. pylori IgG(+), CagA ≥ 15, <234.8 (1.8-12.6)0.0013
H. pylori IgG(+), CagA ≥ 233.2 (1.5-7.0)0.0027
Current smoker4.6 (2.1-10.2)<0.001
Stomach dose (Gy), nonsmoker4.0 (1.00-6.9)0.0457
Stomach dose (Gy), smoker1.2 (0.6-1.8)>0.5
  • NOTE: A histologic-type term (diffuse versus intestinal) and interaction terms between histologic-type and other possible risk factors except for CAG in the table were included in a model to directly evaluate differences. Point estimates of RR are shown for both intestinal-type and diffuse-type noncardia gastric cancer, but the difference between types was significant at the 0.05 level only for the risk factor “current smoker.”